P. Kelly Marcom

1993–2024 年に発表

80
論文数
21,632
被引用数
67
h 指数
80
i10 指数

被引用数

P. Kelly Marcom の年別被引用数1995 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 2 件2000 年: 被引用 4 件2001 年: 被引用 5 件2002 年: 被引用 9 件2003 年: 被引用 5 件2004 年: 被引用 20 件2005 年: 被引用 52 件2006 年: 被引用 100 件2007 年: 被引用 109 件2008 年: 被引用 123 件2009 年: 被引用 151 件2010 年: 被引用 192 件2011 年: 被引用 190 件2012 年: 被引用 226 件2013 年: 被引用 227 件2014 年: 被引用 252 件2015 年: 被引用 253 件2016 年: 被引用 238 件2017 年: 被引用 219 件2018 年: 被引用 178 件2019 年: 被引用 648 件2020 年: 被引用 743 件2021 年: 被引用 728 件2022 年: 被引用 546 件2023 年: 被引用 371 件2024 年: 被引用 495 件2025 年: 被引用 210 件2026 年: 被引用 9 件1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,966 件、この内訳の 30.8%中国: 引用元論文 888 件、この内訳の 9.2%イギリス: 引用元論文 555 件、この内訳の 5.7%イタリア: 引用元論文 525 件、この内訳の 5.4%ドイツ: 引用元論文 404 件、この内訳の 4.2%カナダ: 引用元論文 382 件、この内訳の 4%フランス: 引用元論文 337 件、この内訳の 3.5%スペイン: 引用元論文 302 件、この内訳の 3.1%オーストラリア: 引用元論文 268 件、この内訳の 2.8%オランダ: 引用元論文 260 件、この内訳の 2.7%スイス: 引用元論文 222 件、この内訳の 2.3%ベルギー: 引用元論文 218 件、この内訳の 2.3%
0%30.8%その他 24%

分野

  • Medicine57.9%
  • Biochemistry, Genetics and Molecular Biology34.8%
  • Computer Science1.4%
  • Engineering1.4%
  • Immunology and Microbiology1.2%
  • Economics, Econometrics and Finance1%
  • その他2.3%

トピック

  • Breast Cancer Treatment Studies8.7%
  • HER2/EGFR in Cancer Research5.8%
  • Advanced Breast Cancer Therapies3.3%
  • BRCA gene mutations in cancer3.3%
  • Cancer Treatment and Pharmacology3.2%
  • Cancer Genomics and Diagnostics3.1%
  • その他72.6%

共著者

全論文

検索で開く
  1. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 被引用: 1,618

  2. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 500

  3. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 165

  4. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julie M. Gastier‐Foster, Mothaffar F. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael A. Davis, Jonathan C. Silverstein, Alexander J. Ropelewski, Minetta C. Liu, Susan G. Hilsenbeck, Larry Norton, Andrea L. Richardson, W. Fraser Symmans, Antonio C. Wolff, Nancy E. Davidson, Lisa A. Carey, Adrian V. Lee, Justin M. Balko, Katherine A. Hoadley, Peter W. Laird, Elaine R. Mardis, Tari A. King, AURORA US Network, Aguirre A. de Cubas, Charles M. Perou - Nature Cancer 2022 被引用: 114

  5. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 748

  6. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 493

  7. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 被引用: 542

  8. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 560

  9. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

    著者: , , , , , - Breast Cancer Research and Treatment 2018 被引用: 198

  10. Whole-genome analysis informs breast cancer response to aromatase inhibition

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis - Nature 2012 被引用: 1,035

  11. Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 913

  12. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Ward, Rashmi Kumar, Dorothy A. Shead - Journal of the National Comprehensive Cancer Network 2018 被引用: 1,616

  13. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 52

  14. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 130

  15. Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

    著者: , , , , , , , , , - Molecular Cancer Research 2011 被引用: 650

  16. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paula R. Pohlmann, Catherine Van Poznak, Andres Forero‐Torres, Minetta C. Liu, Kathryn J. Ruddy, Adrienne G. Waks, Michelle K. DeMeo, Harold J. Burstein, Ann H. Partridge, Patrizia Dell’Orto, Leila Russo, Emma Krause, Daniel Newhouse, Busem Binboğa Kurt, Elizabeth A. Mittendorf, Bryan P. Schneider, Aleix Prat, Eric P. Winer, Ian E. Krop, Sara M. Tolaney, Romualdo Barroso‐Sousa, Giuseppe Curigliano, Molly DiLullo, Winnie W. Hui, Christian Kirkup, Giuseppe Viale, Yue Zheng - Journal of Clinical Oncology 2024 被引用: 38

  17. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

    著者: , , , , , , , , , , - Annals of Surgical Oncology 2013 被引用: 226

  18. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , L. F. Carson, Diana Dickson-Witmer, Gyungyub Gong, Jimmy Green, Chih‐Yi Hsu, Ling‐Ming Tseng, Judith R. Kroep, A. Marilyn Leitch, Venetia Sarode, E. Mamounas, P. Kelly Marcom, Paolo Nucíforo, Soonmyung Paik, Vicente Peg, David Peston, Jean‐Yves Pierga, Miguel Quintela-Fandiño, Roberto Salgado, William M. Sikov, Jeremy Thomas, Gary Unzeitig, Jelle Wesseling - Annals of Oncology 2015 被引用: 238

  19. Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study

    著者: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 80

  20. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

    著者: , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 604

  21. Breast Cancer, Version 3.2018

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jessica Young, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2019 被引用: 199

  22. Randomized Trial of Telegenetics vs. In‐Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance

    著者: , , , , , , , , , - Journal of Genetic Counseling 2015 被引用: 184

  23. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 被引用: 57

  24. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 280